Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals.

Neurobiology of aging·2026
Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effect of Parity and β-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women.

Neurology·2026
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma phosphorylated tau217 discordance with amyloid status in an ethnically diverse mixed memory clinic cohort.

Journal of the neurological sciences·2026
Same author

Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.

Communications medicine·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Gemma Salvadó1,2, Kanta Horie3,4,5,6, Nicolas R Barthélemy6,7

  • 1Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

一个新的阿尔茨海默病 (AD) 阶段测定系统使用了血%p-tau217和eMTBR-tau243生物标志物. 这种非侵入性方法准确地分阶段AD进展,提供一个可扩展的替代PET扫描.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物发现发现
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 对生物阿尔茨海默病 (AD) 的准确分期对于临床试验和治疗开发至关重要.
  • 目前的血生物标志物缺乏针对晚期AD阶段的特异性.
  • 这项研究引入了一种新的分期方法,使用两个高性能等离子体生物标志物:%p-tau217和eMTBR-tau243.

研究的目的:

  • 开发和验证一种可扩展,低侵入性的方法,用于阿尔茨海默病 (AD) 的生物分期.
  • 评估血%p-tau217和eMTBR-tau243在反映AD病理和进展方面的有用性.

主要方法:

  • 包括来自BioFINDER-2研究的764人,覆盖了AD连续.
  • 使用质谱法测量了血%p-tau217和eMTBR-tau243水平.
  • 结合生物标志物系统被用来定义五个基于血的AD阶段 (阶段-0到阶段-5),与PET成像和认知测量相比.

主要成果:

  • 在eMTBR-tau243之前,血%p-tau217水平增加,这表明了序列生物标志物的动态.
  • 较高的血生物标志物阶段与异常的粉样β和蛋白PET成像以及认知衰退有显著的相关性.
  • 基于等离子体的分期系统在预测基于PET和临床AD阶段方面表现出高准确性.

结论:

  • 血%p-tau217和eMTBR-tau243的组合可以准确地确定阿尔茨海默病的生物学阶段.
  • 这种基于等离子体的方法是非侵入性的,可扩展的,并为基于CSF或PET的分期提供了切实可行的替代方案.
  • 这种方法有助于改善临床试验和疾病管理的患者分层.